Stable heterodimeric antibody design with mutations in the Fc domain
The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.
1. A mammalian host cell comprising nucleic acid encoding a heteromultimer comprising a modified heterodimeric CH3 domain comprising a first CH3 domain polypeptide and a second CH3 domain polypeptide, the first and second CH3 domain polypeptides independently comprising amino acid modifications as compared to a wild-type CH3 domain polypeptide,
wherein the first CH3 domain polypeptide comprises amino acid modifications at positions T350, L351, F405, and Y407, and the second CH3 domain polypeptide comprises amino acid modifications at positions T350, T366, K392 and T394,
wherein the amino acid modification at position T350 is T350V, T350I, T350L or T350M; the amino acid modification at position L351 is L351Y; the amino acid modification at position F405 is F405A, F405V, F405T or F405S; the amino acid modification at position Y407 is Y407V, Y407A or Y407I; the amino acid modification at position T366 is T366L, T366I, T366V or T366M, the amino acid modification at position K392 is K392F, K392L or K392M, and the amino acid modification at position T394 is T394W
wherein the modified heterodimeric CH3 domain is comprised by a Fc construct based on a type G immunoglobulin (IgG), and
wherein the numbering of amino acid residues is according to the EU index as set forth in Kabat.
2. The mammalian host cell according to claim 1 , wherein the heterodimeric CH3 domain has a melting temperature (Tm) of between 74° C. and about 83° C. and a purity of at least 95%.
3. The mammalian host cell according to claim 1 , wherein the amino acid modification at position K392 is K392M or K392L.
4. The mammalian host cell according to claim 1 , wherein the amino acid modification at position T350 is T350V.
5. The mammalian host cell according to claim 3 , wherein:
(a) the first CH3 domain polypeptide further comprises one or more amino acid modifications selected from Q347R and one of S400R or S400E; or
(b) the second CH3 domain polypeptide further comprises one or more amino acid modifications selected from L351Y, K360E, and one of N390R, N390D or N390E; or
(c) the first CH3 domain polypeptide further comprises one or more amino acid modifications selected from Q347R and one of S400R or S400E, and the second CH3 domain polypeptide further comprises one or more amino acid modifications selected from L351Y, K360E, and one of N390R, N390D or N390E.
6. The mammalian host cell according to claim 3 , wherein the amino acid modification at position T350 is T350V.
7. The mammalian host cell according to claim 6 , wherein:
(a) the amino acid modification at position F405 is F405A; and/or
(b) the amino acid modification at position Y407 is Y407V; and/or
(c) the amino acid modification at position T366 is T366L or T366I.
8. The mammalian host cell according to claim 4 , wherein:
(a) the amino acid modification at position F405 is F405A; and/or
(b) the amino acid modification at position Y407 is Y407V; and/or
(c) the amino acid modification at position T366 is T366L or T366I.
9. The mammalian host cell according to claim 4 , wherein the amino acid modification at position F405 is F405A, the amino acid modification at position Y407 is Y407V, the amino acid modification at position T366 is T366L or T366I, and the amino acid modification at position K392 is K392L or K392M.
10. The mammalian host cell according to claim 1 , wherein the amino acid modification at position F405 is F405A, the amino acid modification at position Y407 is Y407V, the amino acid modification at position T366 is T366L or T366I, and the amino acid modification at position K392 is K392M or K392L.
11. The mammalian host cell according to claim 5 , wherein:
(a) the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405V and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392M and T394W; or
(b) the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405T and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392M and T394W; or
(c) the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405S and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392M and T394W; or
(d) the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, T366L, N390R, K392M and T394W; or
(e) the first CH3 domain polypeptide comprises the amino acid modifications Q347R, T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, K360E, T366L, N390R, K392M and T394W; or
(f) the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400R, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390D, K392M and T394W; or
(g) the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400R, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390E, K392M and T394W; or
(h) the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392L and T394W; or
(i) the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392F and T394W; or
(j) the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400R, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, K392M and T394W.
12. The mammalian host cell according to claim 1 , wherein the first CH3 domain polypeptide further comprises the amino acid modification Y349C, and the second CH3 domain polypeptide further comprises the amino acid modification S354C.
13. The mammalian host cell according to claim 12 , wherein the first CH3 domain polypeptide comprises the amino acid modifications Y349C, T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, S354C, T366L, N390R, K392M and T394W.
14. The mammalian host cell according to claim 1 , wherein the IgG is an IgG1.
15. The mammalian host cell according to claim 1 , wherein the heteromultimer is a bispecific antibody or a multispecific antibody.
16. The mammalian host cell according to claim 15 , wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain that binds a cancer antigen.
17. The mammalian host cell according to claim 16 , wherein the cancer antigen is HER2, HER3 or EGFR.
18. A mammalian host cell comprising nucleic acid encoding a heteromultimer comprising a modified heterodimeric CH3 domain comprising:
a first CH3 domain polypeptide comprising amino acid modifications T350V, L351Y, F405A and Y407V, and
a second CH3 domain polypeptide comprising amino acid modifications T350V, T366L, K392L and T394W, and
wherein the modified heterodimeric CH3 domain is comprised by a Fc construct based on a type G immunoglobulin (IgG).
19. The mammalian host cell according to claim 18 , wherein the IgG is an IgG1.
20. The mammalian host cell according to claim 18 , wherein the heteromultimer is a bispecific antibody or a multispecific antibody.
21. The mammalian host cell according to claim 20 , wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain that binds a cancer antigen.
22. The mammalian host cell according to claim 21 , wherein the cancer antigen is HER2, HER3 or EGFR.
23. A mammalian host cell comprising nucleic acid encoding a heteromultimer comprising a modified heterodimeric CH3 domain comprising:
a first CH3 domain polypeptide comprising amino acid modifications T350V, L351Y, F405A and Y407V, and
a second CH3 domain polypeptide comprising amino acid modifications T350V, T366L, K392M and T394W, and
wherein the modified heterodimeric CH3 domain is comprised by a Fc construct based on a type G immunoglobulin (IgG).
24. The mammalian host cell according to claim 23 , wherein the IgG is an IgG1.
25. The mammalian host cell according to claim 23 , wherein the heteromultimer is a bispecific antibody or a multispecific antibody.
26. The mammalian host cell according to claim 25 , wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain that binds a cancer antigen.
27. The mammalian host cell according to claim 26 , wherein the cancer antigen is HER2, HER3 or EGFR.
28. A mammalian host cell comprising nucleic acid encoding a heteromultimer comprising a modified heterodimeric CH3 domain comprising:
a first CH3 domain polypeptide comprising amino acid modifications T350V, L351Y, S400E, F405A and Y407V, and
a second CH3 domain polypeptide comprising amino acid modifications T350V, T366L, N390R, K392M and T394W, and
wherein the modified heterodimeric CH3 domain is comprised by a Fc construct based on a type G immunoglobulin (IgG).
29. The mammalian host cell according to claim 28 , wherein the IgG is an IgG1.
30. The mammalian host cell according to claim 28 , wherein the heteromultimer is a bispecific antibody or a multispecific antibody.
31. The mammalian host cell according to claim 30 , wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain that binds a cancer antigen.
32. The mammalian host cell according to claim 31 , wherein the cancer antigen is HER2, HER3 or EGFR.